Ken Griffin Sana Biotechnology, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.76 - $6.86 $206,800 - $377,300	-55,000 Reduced 54.56%	45,800 $190,000
Q2 2024 Aug 14, 2024	BUY	$5.23 - $10.44 $124,474 - $248,472	23,800 Added 30.91%	100,800 $550,000
Q1 2024 May 15, 2024	BUY	$4.2 - $11.27 $202,440 - $543,214	48,200 Added 167.36%	77,000 $770,000
Q4 2023 Feb 14, 2024	BUY	$2.8 - $4.55 $54,320 - $88,270	19,400 Added 206.38%	28,800 $117,000
Q3 2023 Nov 14, 2023	SELL	$3.77 - $6.23 $326,105 - $538,895	-86,500 Reduced 90.2%	9,400 $36,000
Q2 2023 Aug 14, 2023	BUY	$3.22 - $7.53 $298,494 - $698,031	92,700 Added 2896.88%	95,900 $571,000
Q1 2023 May 15, 2023	BUY	$3.11 - $4.92 $7,464 - $11,808	2,400 Added 300.0%	3,200 $10,000
Q4 2022 Feb 14, 2023	SELL	$3.19 - $6.46 $31,900 - $64,600	-10,000 Reduced 92.59%	800 $3,000
Q3 2022 Nov 14, 2022	SELL	$5.58 - $9.04 $94,860 - $153,680	-17,000 Reduced 61.15%	10,800 $65,000

175

121M

1.87M

1.48M

Ticker SANA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 190,232,000
Market Cap $460M
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.